Responses of growth hormone to desipramine in endogenous and non-endogenous depression.
Desipramine, a monoamine reuptake inhibitor, was used to stimulate release of growth hormone (GH) in 29 DSM-III major depressives and in 10 healthy controls. Eighteen of the depressives showed a blunted response. The GH-stimulation test was unable to distinguish endogenous from non-endogenous patients. The 13 dexamethasone non-suppressors were more likely to have a blunted GH response than the 14 suppressors. The results indicate that at least a subset of non-endogenous depressives have significant neuroendocrine abnormality.
Dinan
T G
TG
Department of Psychiatry, Trinity College Medical School, St James's Hospital, Dublin, Ireland.
Barry
S
S
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000523:psychology; D003866:Depressive Disorder / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000523:psychology; D003891:Desipramine; D003907:Dexamethasone; D003937:Diagnosis, Differential; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000523:psychology
D003907:Dexamethasone; D013006:Growth Hormone; D003891:Desipramine